Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2012

01-04-2012 | Commentary

Is FTO a type 2 diabetes susceptibility gene?

Author: D. Meyre

Published in: Diabetologia | Issue 4/2012

Login to get access

Excerpt

Obesity is a major predictor of future risk of type 2 diabetes [1] and the escalating prevalence of type 2 diabetes worldwide is mainly attributable to the continued rise in obesity observed over the last decades [2]. Identification of the complex interactions and shared molecular pathways linking obesity and type 2 diabetes is an area of intense research [3]. Human molecular genetics in particular has led to the identification of numerous molecular determinants of obesity and type 2 diabetes and to the global conclusion that the genes involved in genetic predisposition towards type 2 diabetes influence pancreatic beta cell function/mass and, to a lesser extent, insulin action, whereas obesity predisposing genes modulate hypothalamic sensing and control of energy balance [4, 5]. To date, few loci have been convincingly associated with both obesity- and type 2 diabetes-related traits, and FTO, in addition to IRS1 [6, 7], ENPP1 [8‐10] or GIPR [11, 12], may be one of the molecular determinants linking obesity and type 2 diabetes. …
Literature
1.
Abdullah A, Peeters A, de Courten M, Stoelwinder J (2010) The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 89:309–319PubMedCrossRef
2.
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378:815–825PubMedCrossRef
3.
Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846PubMedCrossRef
4.
O’Rahilly S (2009) Human genetics illuminates the paths to metabolic disease. Nature 462:307–314PubMedCrossRef
5.
6.
Rung J, Cauchi S, Albrechtsen A et al (2009) Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 41:1110–1115PubMedCrossRef
7.
Kilpelainen TO, Zillikens MC, Stancakova A et al (2011) Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 43:753–760PubMedCrossRef
8.
Meyre D, Bouatia-Naji N, Tounian A et al (2005) Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 37:863–867PubMedCrossRef
9.
Wang R, Zhou D, Xi B et al (2011) ENPP1/PC-1 gene K121Q polymorphism is associated with obesity in European adult populations: evidence from a meta-analysis involving 24,324 subjects. Biomed Environ Sci 24:200–206PubMed
10.
McAteer JB, Prudente S, Bacci S et al (2008) The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 57:1125–1130PubMedCrossRef
11.
Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142–148PubMedCrossRef
12.
Speliotes EK, Yerges-Armstrong LM, Wu J et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324PubMedCrossRef
13.
Frayling TM, Timpson NJ, Weedon MN et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894PubMedCrossRef
14.
Dina C, Meyre D, Gallina S et al (2007) Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 39:724–726PubMedCrossRef
15.
Scuteri A, Sanna S, Chen WM et al (2007) Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 3:e115PubMedCrossRef
16.
Hinney A, Nguyen TT, Scherag A et al (2007) Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One 2:e1361PubMedCrossRef
17.
Hertel JK, Johansson S, Sonestedt E et al (2011) FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP Studies. Diabetes 60:1637–1644PubMedCrossRef
18.
Li H, Kilpeläinen TO, Liu C et al (2012) Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia doi:10.​1007/​s00125-011-2370-7
19.
Muller MJ, Bosy-Westphal A, Krawczak M (2010) Genetic studies of common types of obesity: a critique of the current use of phenotypes. Obes Rev 11:612–618PubMedCrossRef
20.
Bergman RN, Stefanovski D, Buchanan TA et al (2011) A better index of body adiposity. Obesity (Silver Spring) 19:1083–1089CrossRef
21.
Hillson RM, Hockaday TD, Newton DJ, Pim B (1985) Delayed diagnosis of non-insulin-dependent diabetes is associated with greater metabolic and clinical abnormality. Diabet Med 2:383–386PubMedCrossRef
22.
Pontiroli AE, Miele L, Morabito A (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13:1008–1019PubMedCrossRef
23.
Lindberg M, Astrup A (2007) The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 8:381–384PubMedCrossRef
24.
Unick JL, Beavers D, Jakicic JM et al (2011) Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34:2152–2157PubMedCrossRef
25.
Meneghini LF, Orozco-Beltran D, Khunti K et al (2011) Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 96:3337–3353PubMedCrossRef
26.
Sovio U, Mook-Kanamori DO, Warrington NM et al (2011) Association between common variation at the FTO locus and changes in body mass index from infancy to late childhood: the complex nature of genetic association through growth and development. PLoS Genet 7:e1001307PubMedCrossRef
27.
Tschritter O, Preissl H, Yokoyama Y, Machicao F, Haring HU, Fritsche A (2007) Variation in the FTO gene locus is associated with cerebrocortical insulin resistance in humans. Diabetologia 50:2602–2603PubMedCrossRef
28.
Pascoe L, Tura A, Patel SK et al (2007) Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes 56:3101–3104PubMedCrossRef
29.
Freathy RM, Timpson NJ, Lawlor DA et al (2008) Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 57:1419–1426PubMedCrossRef
30.
Do R, Bailey SD, Desbiens K et al (2008) Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes 57:1147–1150PubMedCrossRef
31.
Shimaoka I, Kamide K, Ohishi M et al (2010) Association of gene polymorphism of the fat-mass and obesity-associated gene with insulin resistance in Japanese. Hypertens Res 33:214–218PubMedCrossRef
32.
Kirkpatrick CL, Marchetti P, Purrello F et al (2010) Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One 5:e11053PubMedCrossRef
33.
Bravard A, Lefai E, Meugnier E et al (2011) FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. Diabetes 60:258–268PubMedCrossRef
34.
Samaras K, Botelho NK, Chisholm DJ, Lord RV (2010) Subcutaneous and visceral adipose tissue FTO gene expression and adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes mellitus and in health. Obes Surg 20:108–113PubMedCrossRef
35.
Poritsanos NJ, Lew PS, Mizuno TM (2010) Relationship between blood glucose levels and hepatic Fto mRNA expression in mice. Biochem Biophys Res Commun 400:713–717PubMedCrossRef
36.
Grunnet LG, Nilsson E, Ling C, Hansen T, Pedersen O, Groop L et al (2009) Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue. Diabetes 58:2402–2408PubMedCrossRef
37.
Russell MA, Morgan NG (2011) Conditional expression of the FTO gene product in rat INS-1 cells reveals its rapid turnover and a role in the profile of glucose-induced insulin secretion. Clin Sci (Lond) 120:403–413CrossRef
38.
Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
39.
Zhou Y, Zhang E, Berggreen C et al (2012) Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mol Genet 21:196–207PubMedCrossRef
40.
Gerken T, Girard CA, Tung YC et al (2007) The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318:1469–1472PubMedCrossRef
41.
Han Z, Niu T, Chang J et al (2010) Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature 464:1205–1209PubMedCrossRef
42.
Wu Q, Saunders RA, Szkudlarek-Mikho M, Serna Ide L, Chin KV (2010) The obesity-associated Fto gene is a transcriptional coactivator. Biochem Biophys Res Commun 401:390–5PubMedCrossRef
43.
Bell CG, Finer S, Lindgren CM, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One 5:e14040.
44.
Toperoff G, Aran D, Kark JD et al (2012) Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 21:371–383PubMedCrossRef
45.
Huang J, Johnson AD, O’Donnell CJ (2011) PRIMe: a method for characterization and evaluation of pleiotropic regions from multiple genome-wide association studies. Bioinformatics 27:1201–1206PubMedCrossRef
46.
Fischer J, Koch L, Emmerling C et al (2009) Inactivation of the Fto gene protects from obesity. Nature 458:894–898PubMedCrossRef
47.
Church C, Lee S, Bagg EA et al (2009) A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet 5:e1000599PubMedCrossRef
48.
Church C, Moir L, McMurray F et al (2010) Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet 42:1086–1092PubMedCrossRef
49.
Li S, Zhao JH, Luan J et al (2010) Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia 54:776–782CrossRef
50.
de Koning L, Gerstein HC, Bosch J et al (2010) Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia 53:1322–1330PubMedCrossRef
51.
Ragvin A, Moro E, Fredman D et al (2010) Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc Natl Acad Sci U S A 107:775–780PubMedCrossRef
Metadata
Title
Is FTO a type 2 diabetes susceptibility gene?
Author
D. Meyre
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2478-4

Other articles of this Issue 4/2012

Diabetologia 4/2012 Go to the issue

Article

Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians

Article

Novel standards in the measurement of rat insulin granules combining electron microscopy, high-content image analysis and in silico modelling

Article

Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways

Then and Now

How the immunoassay transformed C-peptide from a duckling into a swan

Article

Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death

Letter

Oral glucose tolerance test in patients with undiagnosed diabetes and coronary artery disease: When should it be performed?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits